ASMI disappointed with TGA fee increases

03 July 2012

Return to Media Release Index

The Australian Self-Medication Industry (ASMI), the industry body representing evidence-based, non-prescription consumer healthcare products, today expressed its disappointment at the rise in fees and charges announced by the Therapeutic Goods Administration (TGA).

The TGA announced a 5.6% increase in fees and charges for 2012-13, including a 2% rise to cover the costs associated with the TGA's Blueprint Reforms.

The Executive Director of ASMI, Dr Deon Schoombie, said that the over-the-counter (OTC) medicines sector was extremely disappointed at the extent of the rise.
"These fee increases are excessive, and impose an unreasonable burden on the medicines industry at a time of challenging economic conditions.

"We acknowledge the merit of cost recovery from industry for services provided by the TGA. However, the inclusion of 2% component to fund the TGA's reforms goes beyond what is reasonable to recover from industry.

"The charges associated with internal business improvement at the TGA should not be passed on to industry.

"It is also disappointing that the consultation process related to the fee increases fell short in terms of both timing and transparency, and that the concerns lodged by the industry were not acted upon.

"ASMI believes that fees and charges should have been maintained at current levels until the outcomes of the OTC Business Review Process have been completed and implemented," Dr Schoombie said.
About ASMI: The Australian Self-Medication Industry (ASMI) is the peak industry body for the Australian self care industry representing consumer healthcare products including over-the-counter medicines and complementary medicines. ASMI's mission is to promote better health through responsible self-care. This means ensuring that safe and effective self-care products are readily available to all Australians at a reasonable cost. ASMI works to encourage responsible use by consumers and an increasing role for cost-effective self-medication products as part of the broad national health strategy.

Media contact: Bob Bowden, Foresight Communications (02) 9241 2811, 0412 753 298